PDCD1 and neoplasm: Since the inclusion criteria of the RCTs on RCC included at least one prior anti-tumor therapy, while those of the other RCTs were no more than one systemic treatment, this difference might partly result in the high incidence of PD-1 inhibitors-related pneumonitis in RCC patients.